NADER EL-MALLAWANY

Concepts (210)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sarcoma, Kaposi
14
2023
120
6.190
Why?
Epstein-Barr Virus Infections
11
2024
291
3.550
Why?
HIV Infections
16
2023
1891
2.380
Why?
Burkitt Lymphoma
9
2024
146
2.310
Why?
Herpesvirus 4, Human
9
2024
671
2.220
Why?
Herpesvirus 8, Human
3
2023
49
1.680
Why?
Lymphoma
4
2023
322
1.590
Why?
Malawi
17
2025
397
1.390
Why?
Lymphoproliferative Disorders
5
2024
224
1.250
Why?
Lymphoma, Non-Hodgkin
4
2023
162
1.250
Why?
Histiocytosis, Langerhans-Cell
4
2024
225
1.230
Why?
Lymphohistiocytosis, Hemophagocytic
2
2021
145
1.230
Why?
Lymphoma, T-Cell, Peripheral
1
2025
15
0.970
Why?
Child
41
2025
24527
0.940
Why?
Organ Transplantation
2
2024
164
0.930
Why?
Lymphoma, Large B-Cell, Diffuse
3
2024
139
0.830
Why?
Kasabach-Merritt Syndrome
1
2023
16
0.820
Why?
Lymphoma, T-Cell
4
2021
64
0.750
Why?
Antineoplastic Combined Chemotherapy Protocols
8
2024
1239
0.710
Why?
Adolescent
27
2025
19358
0.680
Why?
Interleukin-6
2
2019
415
0.680
Why?
Disease Susceptibility
1
2021
297
0.660
Why?
Anemia
2
2023
341
0.640
Why?
Viral Load
4
2018
384
0.610
Why?
Antiretroviral Therapy, Highly Active
3
2020
266
0.590
Why?
Cytokines
3
2021
1279
0.580
Why?
Herpesviridae Infections
1
2018
142
0.570
Why?
Humans
53
2025
124405
0.520
Why?
Vincristine
5
2020
196
0.520
Why?
Antineoplastic Agents
3
2020
1674
0.450
Why?
Lymphoma, B-Cell
2
2025
141
0.420
Why?
Rituximab
3
2024
156
0.400
Why?
Hematopoietic Stem Cell Transplantation
5
2025
1199
0.390
Why?
Child, Preschool
16
2025
14085
0.390
Why?
Neoplasms
4
2025
2801
0.380
Why?
Methotrexate
3
2025
351
0.380
Why?
Hydroa Vacciniforme
1
2010
3
0.360
Why?
Male
27
2025
61028
0.330
Why?
AIDS-Related Opportunistic Infections
2
2020
136
0.330
Why?
Disease Management
2
2025
519
0.320
Why?
Young Adult
12
2024
8979
0.320
Why?
Female
27
2025
66305
0.310
Why?
Tanzania
3
2023
68
0.290
Why?
T-Lymphocytes, Cytotoxic
1
2010
501
0.280
Why?
Prognosis
6
2025
4554
0.280
Why?
Bone Marrow
3
2021
325
0.270
Why?
Neoplasm Staging
3
2019
1218
0.260
Why?
Immunotherapy
4
2022
662
0.260
Why?
Prospective Studies
8
2025
6089
0.260
Why?
Retrospective Studies
9
2025
16233
0.250
Why?
Laboratories, Hospital
1
2025
21
0.240
Why?
Skin Neoplasms
3
2023
803
0.240
Why?
Infant
9
2025
12479
0.240
Why?
Doxorubicin
3
2020
301
0.220
Why?
Socioeconomic Factors
2
2017
872
0.220
Why?
Antimetabolites, Antineoplastic
1
2025
188
0.220
Why?
Proto-Oncogene Proteins c-bcl-2
1
2024
173
0.210
Why?
Lymphomatoid Papulosis
1
2023
3
0.210
Why?
Cyclophosphamide
3
2020
421
0.210
Why?
Mycosis Fungoides
1
2023
14
0.210
Why?
Treatment Outcome
11
2025
12287
0.210
Why?
HIV-1
2
2016
463
0.200
Why?
Adult
9
2024
29397
0.200
Why?
Mucositis
1
2022
18
0.200
Why?
Morbidity
1
2023
244
0.200
Why?
Haploinsufficiency
1
2024
257
0.200
Why?
Africa South of the Sahara
2
2020
119
0.200
Why?
MAP Kinase Signaling System
1
2024
316
0.200
Why?
Molecular Targeted Therapy
2
2015
353
0.200
Why?
Translocation, Genetic
1
2024
356
0.190
Why?
Medical Oncology
1
2023
216
0.190
Why?
Perforin
1
2021
17
0.190
Why?
Killer Cells, Natural
2
2021
324
0.180
Why?
Virus Replication
1
2023
610
0.170
Why?
Cysticercosis
1
2020
21
0.170
Why?
T-Lymphocyte Subsets
1
2021
196
0.170
Why?
Bleomycin
2
2020
150
0.170
Why?
Pregnancy Complications, Neoplastic
1
2020
61
0.170
Why?
Protein Kinase Inhibitors
1
2024
532
0.170
Why?
Lymphadenopathy
1
2019
29
0.160
Why?
Anthracyclines
2
2017
36
0.160
Why?
Tertiary Healthcare
1
2019
21
0.160
Why?
Clinical Decision-Making
1
2021
267
0.160
Why?
Endemic Diseases
1
2018
57
0.150
Why?
HIV Protease Inhibitors
1
2018
53
0.150
Why?
Anti-HIV Agents
2
2020
314
0.150
Why?
Virus Activation
1
2018
87
0.150
Why?
Biopsy
1
2021
1236
0.140
Why?
Withholding Treatment
1
2017
68
0.140
Why?
Hodgkin Disease
2
2017
293
0.140
Why?
Asia
1
2017
107
0.140
Why?
Plasma
1
2017
96
0.130
Why?
Europe
1
2017
352
0.130
Why?
HIV
1
2017
180
0.130
Why?
Risk
1
2017
749
0.120
Why?
Developing Countries
1
2017
268
0.120
Why?
Remission Induction
1
2016
301
0.120
Why?
Cross-Sectional Studies
1
2023
3427
0.120
Why?
Angiomatosis, Bacillary
1
2014
3
0.120
Why?
Algorithms
1
2021
1612
0.110
Why?
Risk Factors
4
2023
10149
0.110
Why?
Pilot Projects
1
2018
1404
0.110
Why?
T-Lymphocytes
3
2019
1697
0.110
Why?
Mass Spectrometry
1
2014
331
0.110
Why?
Proto-Oncogene Proteins B-raf
2
2024
168
0.100
Why?
Child Health Services
1
2013
88
0.100
Why?
Biomarkers
1
2021
2980
0.100
Why?
Adenoviridae Infections
1
2011
70
0.090
Why?
Neoplasm Recurrence, Local
3
2024
1127
0.090
Why?
Proteomics
1
2014
491
0.090
Why?
Patient-Centered Care
1
2013
225
0.090
Why?
Genetic Predisposition to Disease
1
2021
3137
0.090
Why?
Recurrence
2
2024
1423
0.090
Why?
Survival Rate
4
2017
2020
0.080
Why?
United States
2
2023
10773
0.080
Why?
Infant, Newborn
2
2025
8184
0.080
Why?
DNA, Viral
3
2017
479
0.080
Why?
Genomics
1
2017
1490
0.080
Why?
Clinical Trials as Topic
1
2013
1086
0.080
Why?
Transcriptome
1
2014
937
0.080
Why?
Diagnosis, Differential
2
2024
1892
0.070
Why?
Mutation
1
2021
5809
0.070
Why?
Cell Line, Tumor
1
2014
3342
0.070
Why?
Cell Proliferation
1
2014
2304
0.070
Why?
Follow-Up Studies
3
2025
5107
0.070
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2014
810
0.070
Why?
CD4 Lymphocyte Count
2
2018
230
0.070
Why?
Cell Differentiation
1
2014
1930
0.070
Why?
Prednisone
2
2019
274
0.070
Why?
Time Factors
1
2016
6273
0.060
Why?
Signal Transduction
1
2017
4535
0.060
Why?
Disease-Free Survival
2
2016
860
0.060
Why?
Lymph Nodes
2
2019
376
0.060
Why?
Adenine Nucleotides
1
2024
41
0.060
Why?
Arabinonucleosides
1
2024
32
0.060
Why?
Chromosomes, Human, Pair 8
1
2024
78
0.060
Why?
Drug Monitoring
1
2025
168
0.050
Why?
Chromosomes, Human, Pair 14
1
2024
100
0.050
Why?
Hyperplasia
1
2024
209
0.050
Why?
Biomarkers, Tumor
2
2024
1460
0.050
Why?
DNA Helicases
1
2024
226
0.050
Why?
Salvage Therapy
1
2024
194
0.050
Why?
Transplantation, Autologous
1
2022
298
0.050
Why?
Seroepidemiologic Studies
1
2021
121
0.050
Why?
Stem Cell Transplantation
1
2022
238
0.040
Why?
Creatinine
1
2022
382
0.040
Why?
Transplantation Conditioning
1
2022
323
0.040
Why?
Chromatin
1
2024
554
0.040
Why?
Anticestodal Agents
1
2020
3
0.040
Why?
Praziquantel
1
2020
11
0.040
Why?
Subcutaneous Tissue
1
2020
15
0.040
Why?
Taenia solium
1
2020
11
0.040
Why?
Autoimmunity
1
2021
172
0.040
Why?
Immunity
1
2021
191
0.040
Why?
Albendazole
1
2020
29
0.040
Why?
Paclitaxel
1
2020
124
0.040
Why?
Middle Aged
4
2024
26460
0.040
Why?
Acquired Immunodeficiency Syndrome
1
2020
235
0.040
Why?
Immunocompromised Host
1
2020
295
0.040
Why?
Genetic Association Studies
1
2021
775
0.040
Why?
Nuclear Proteins
1
2024
1272
0.040
Why?
Anti-Retroviral Agents
1
2019
140
0.040
Why?
Proto-Oncogenes
1
2017
37
0.040
Why?
Drug Therapy, Combination
1
2020
1154
0.030
Why?
Antibiotics, Antineoplastic
1
2017
127
0.030
Why?
Viremia
1
2016
128
0.030
Why?
Pregnancy Complications, Infectious
1
2020
449
0.030
Why?
Sialic Acid Binding Ig-like Lectin 2
1
2014
3
0.030
Why?
Genetic Testing
1
2021
1004
0.030
Why?
Antigens, CD20
1
2014
37
0.030
Why?
Risk Assessment
2
2016
3382
0.030
Why?
Antibodies, Monoclonal, Murine-Derived
1
2014
63
0.030
Why?
Transcription Factors
1
2024
2607
0.030
Why?
Central Nervous System Neoplasms
1
2016
197
0.030
Why?
Antigens, CD19
1
2014
176
0.030
Why?
Proportional Hazards Models
1
2017
1320
0.030
Why?
Adoptive Transfer
1
2014
237
0.030
Why?
Immune Reconstitution Inflammatory Syndrome
1
2013
18
0.030
Why?
Botswana
1
2013
76
0.030
Why?
Child Nutrition Disorders
1
2013
76
0.030
Why?
Longitudinal Studies
1
2016
1333
0.030
Why?
Gene Expression
1
2017
1569
0.020
Why?
Mouth Neoplasms
1
2013
83
0.020
Why?
Health Services Accessibility
1
2017
605
0.020
Why?
Sex Factors
1
2016
1267
0.020
Why?
Liver
1
2019
1761
0.020
Why?
Recombinant Fusion Proteins
1
2014
767
0.020
Why?
Thrombocytopenia
1
2013
226
0.020
Why?
Incidence
1
2018
3086
0.020
Why?
Animals
2
2024
34145
0.020
Why?
Japan
1
2011
133
0.020
Why?
Receptors, Antigen, T-Cell
1
2014
481
0.020
Why?
Gene Expression Profiling
1
2017
1695
0.020
Why?
Transplantation, Homologous
1
2011
662
0.020
Why?
Cell Separation
1
2010
229
0.020
Why?
Age Factors
1
2016
2805
0.020
Why?
Kaplan-Meier Estimate
1
2011
1017
0.020
Why?
RNA, Viral
1
2011
539
0.020
Why?
Antibodies, Monoclonal
1
2014
1015
0.020
Why?
In Situ Hybridization, Fluorescence
1
2010
764
0.020
Why?
B-Lymphocytes
1
2011
525
0.020
Why?
Flow Cytometry
1
2010
802
0.020
Why?
Pregnancy
1
2020
7167
0.020
Why?
Combined Modality Therapy
1
2011
1245
0.020
Why?
Graft vs Host Disease
1
2011
543
0.020
Why?
Polymerase Chain Reaction
1
2011
1584
0.020
Why?
Mice
1
2024
17728
0.020
Why?
Chronic Disease
1
2011
1186
0.020
Why?
Immunohistochemistry
1
2010
1684
0.020
Why?
Aged
1
2024
19479
0.020
Why?
EL-MALLAWANY's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (210)
Explore
_
Co-Authors (52)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_